Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Basilea provides portfolio status update
Clinical portfolio substantially strengthened through business development in 2023; two phase 3 studies expected to start in 2024Cresemba in-market sales of USD 445 million, increased 22% year-on-year, in 12-month period ending September 2023; 6-months market exclusivity extension granted in the USFDA PDUFA target action date on ceftobiprole US NDA April 3; US commercialization partner expected to be announced prior to FDA decision Allschwil, Switzerland, January 5, 2024 ...
Nasdaq GlobeNewswire
05/01/2024
Cambridge University Hospitals Pioneers NHS Collaboration with uPerform to…
CUH is a family of hospitals, including Addenbrooke's and The Rosie, delivering expert care to over 4.5 million people locally, regionally and nationally as part of England's National Health Service (NHS). CUH was the first NHS trust to implement Epic in the United Kingdom and the first NHS trust to achieve HIMSS EMRAM Stage 7. With over 10,500 staff, CUH was seeking innovative ways to scale its Epic education programme to further support onboarding of new hires, continuous learning and skills…
PR Newswire
05/01/2024
Therabody, the Global Leader In Wellness Technology, Defends Against Recent…
Therabody has combined education, innovation, and well over a decade of pioneering within the tech wellness space to make wellness more accessible for everybody. With a portfolio of almost 600 granted patents globally and over 200 more patent applications pending, Therabody is the industry leader in percussive therapy innovation. Therabody has combined education, innovation, and well over a decade of pioneering within the tech wellness space to make wellness more accessible forevery body...
PR Newswire
04/01/2024
Galapagos enters into strategic collaboration agreement with Thermo Fisher…
Thermo Fisher Scientific to provide CAR-T manufacturing and kitting services for Galapagos' point-of-care CAR-T product candidate in the San Francisco areaAgreement follows previously announced collaboration with Landmark Bio for decentralized CAR-T manufacturing in the Boston area Mechelen, Belgium; 4 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration agreement with Thermo Fisher Scientific, Inc...
Nasdaq GlobeNewswire
04/01/2024
Ultimovacs ASA: Mandatory notification of trade by primary insider
This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act. Attachment 20240104 - Ultimovacs Notification of trade - CDS - KRT 1500
Nasdaq GlobeNewswire
04/01/2024
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
Press ReleaseCrossject engages Syneos Health forU.S. commercial launch of ZEPIZURE ®Crossject expanding market access activities in preparation for filing for marketing authorizationZEPIZURE ®, previously known as ZENEO ®Midazolam, is separately contracted with BARDA for U.S. advanced regulatory development and specific supply to the Strategic National Stockpile Dijon, France, January 4, 2024, 18:00 CET --Crossject (ISIN: FR0011716265; uronext: ALCJ), a specialty...
Nasdaq GlobeNewswire
04/01/2024
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare…
Saint-Herblain (France), January 4, 2024– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that members of its management team including Thomas Lingelbach, CEO and Peter Bühler, CFO will hold investor meetings during the 42 ndAnnual J.P. Morgan Healthcare Conference, January 8 – 10, 2024 in San Francisco and virtually at the Oddo BHF Forum on January 15,2024.Valneva's CEO and CFO will notably discuss the Company's advanced vaccine development...
Nasdaq GlobeNewswire
04/01/2024
Surgical Equipment Market Size to Grow USD 59 Billion by 2032 at a CAGR of 5.2%…
Claim Your Free Sample Now: https://reports.valuates.com/request/sample/ALLI-Manu-2B105/Surgical_Equipment_Market Claim Your Free Sample Now: https://reports.valuates.com/request/sample/ALLI-Manu-2B105/Surgical_Equipment_Market Major Factors Driving the Growth of Surgical Equipment Market: A number of factors are coming together to drive the growth of the surgical equipment market. These factors include an increase in ambulatory surgical centers, a shift towards minimally invasive...
PR Newswire
04/01/2024
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement…
KAT6A is known to play an important role in several cancers. Overexpression of KAT6A correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer, the most common subtype of breast cancer. In preclinical studies, the molecule has demonstrated potent inhibition against KAT6A in multiple CDX and PDX models with good efficacy and safety. Insilico presented data on the molecule at the San Antonio Breast Cancer Symposium in early December. KAT6A is known to play an important...
PR Newswire
04/01/2024
Immunovia announces financial calendar for financial year 2024
Year-End 2023 Report February 21, 2024 Annual Report to be published March 15, 2024 Q1 Report, 2024 ...
PR Newswire
04/01/2024
Pharmaceutical Excipients Market Worth $13.9 Billion | MarketsandMarkets
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=956 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=956 Browse in-depth TOC on "Pharmaceutical Excipients Market" 760 - Tables 45 - Figures 503 - Pages Pharmaceutical Excipients Market Scope: The organic chemicals segment dominated the market share in 2022 for the product segment. Based on product, the global pharmaceutical...
PR Newswire
04/01/2024
Ball Bearing Market to Attain a Valuation of USD 148.3 billion by 2031…
Download Sample PDF of the Report:https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85895 Download Sample PDF of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85895 As long as industry players continue to invest in research and development, innovative bearing solutions will likely be developed that meet evolving industry needs. Changes in manufacturing standards, environmental impacts, and safety regulations may...
PR Newswire
04/01/2024
Digital PCR Market Size to Grow USD 1,305.30 Million by 2030 at a CAGR of 8.6% |…
Claim Your Free Sample Now: https://reports.valuates.com/request/sample/ALLI-Manu-4P27/Digital_PCR_Market Claim Your Free Sample Now: https://reports.valuates.com/request/sample/ALLI-Manu-4P27/Digital_PCR_Market Major Factors Driving the Growth of Digital PCR Market: The demand for accurate nucleic acid quantification, growing applications in clinical diagnostics, increased research and development activities, significant investments and funding support, growing adoption in ...
PR Newswire
04/01/2024
Medical Tubing Market to Hit USD 19.7 billion by 2031, at a CAGR 8.1% | Says…
Advances in materials science and the development of new polymers and coatings offer great potential for improving the performance and functionality of medical tubing. Flexible, biocompatible, and durable materials may contribute to market growth. Medical tubing production and usage can be affected by changes to regulatory standards. The medical industry relies heavily on compliance with safety and quality standards. Advances in materials science and the development of new polymers and…
PR Newswire
04/01/2024
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
stquarter 2024.The new four-story building, to be located close to the existing 46,000 ft 2manufacturing and R&D facility, will provide key infrastructure to support commercialization plans for the company's Natrunix rheumatology program. The new 46,000+ft 2facility will house clinical and medical operations, commercialization teams, and even incorporate wet laboratories, especially to enable ongoing infectious disease programs. In keeping with XBiotech's desire to preserve the...
Nasdaq GlobeNewswire
04/01/2024
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
stquarter 2024.The new four-story building, to be located close to the existing 46,000 ft 2manufacturing and R&D facility, will provide key infrastructure to support commercialization plans for the company's Natrunix rheumatology program. The new 46,000+ft 2facility will house clinical and medical operations, commercialization teams, and even incorporate wet laboratories, especially to enable ongoing infectious disease programs. In keeping with XBiotech's desire to preserve the...
Nasdaq GlobeNewswire
04/01/2024
Alamar Biosciences Announces Commercial Launch of the ARGO™ HT System and the…
"We are thrilled to bring this game-changing platform to the market as it solves a huge unmet need in biomarker analysis for an automated solution for high sensitivity, multiplexed detection of proteins," said Dr. Yuling Luo, Founder, Chairman and CEO of Alamar. "Last year we completed over 80 technology access projects and researchers' response to the data has been overwhelmingly positive. We have already received 10 purchase orders from participants in our early access program…
PR Newswire
04/01/2024
Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a…
- Avenzo also obtains an exclusive option to an additional preclinical program planned for Investigational New Drug (IND) submission in early 2025 - Avenzo also obtains an exclusive option to an additional preclinical program planned for Investigational New Drug (IND) submission in early 2025 SAN DIEGO, Calif.andNATICK, Mass.,Jan. 4, 2024/PRNewswire/ -- Avenzo Therapeutics, Inc. (Avenzo), a clinical-stage biotechnology company developing next generation oncology therapeutics,...
PR Newswire
04/01/2024
EG427 Announces New Preclinical Results from Multiple Studies of EG110A in…
EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB)In a non-clinical pharmacology study in an OAB model, EG110A showed similar efficacy and a strong safety profile compared to botulinum toxin A, notably without the increase in post-void residual urine volume, a known adverse reaction in NDO and OAB with botulinum toxin AIn a long-term non-clinical kinetic study, EG110A demonstrated persistent...
Nasdaq GlobeNewswire
04/01/2024
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery…
Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer Recursion(NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from the companies' fibrosis research collaboration. The compound represents a novel approach to treating fibrotic diseases with compelling early data suggesting the...
Nasdaq GlobeNewswire
04/01/2024
ITM Announces Operational Readiness for NOVA Facility, the World's Largest…
Receipt of Radioactive Material Handling License (RAM License) for production of n.c.a. Lutetium-177Progress demonstrates company's ability to rapidly increase GMP manufacturing capabilities to further supply growing demand for radiopharmaceuticals Garching / Munich, January 4, 2024 –ITM Isotope Technologies Munich SE(ITM) ,a leading radiopharmaceutical biotech company, today announced the receipt of the Radioactive Material Handling License (RAM License) for the...
Nasdaq GlobeNewswire
04/01/2024
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment...
Nasdaq GlobeNewswire
04/01/2024
ADC Therapeutics Provides Business Updates
ZYNLONTA ®14Q 2023 net sales expected to be ~$16.5 million, a double-digit percentage increase as compared to 3Q 2023LOTIS-7: Study of ZYNLONTA in combination with bispecifics cleared first dosing cohort with no DLT and with early signs of efficacyADCT-601 (targeting AXL): Reached MTD and currently in dose optimization; Early signs of antitumor activity in both monotherapy and in combinationMultiple data catalysts expected in 2024 and with a cash runway now expected into...
Nasdaq GlobeNewswire
04/01/2024
MAMMOTION Introduces YUKA, 3D Vision Robotic Mower with Self-Emptying Sweeper…
As MAMMOTION's most advanced lawn maintenance solution for small and mid-sized properties, YUKA brings next generation Lawn Mower and sweeper in one with key features as follow: As MAMMOTION's most advanced lawn maintenance solution for small and mid-sized properties, YUKA brings next generation Lawn Mower and sweeper in one with key features as follow: Beyond simplifying lawn care, YUKA brings peace of mind benefits with smart home voice control capabilities, smart rain detection,...
PR Newswire
04/01/2024
Altri Comunicati
